Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)

• Status: Completed
• Trial end date: 2009-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a year-long study evaluating the efficacy of both daily and intermittent treatment of asthma in children who experience symptoms episodically (i.e., seasonally, usually in the context of upper respiratory tract infection).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Montelukast

Criteria

Inclusion Criteria:

• Patients aged 6 months to 5 years with episodic (periodic) asthma

Exclusion Criteria:

• Patients who are not in otherwise good health

• Patients who have persistent asthma (continual asthma symptoms)